The incidence of cutaneous melanoma is rising steadily, and the rate of increase is among the highest for any form of cancer. Although the reliability of age as a prognostic factor is debatable, several studies suggest that age has an important prognostic use.
166.0±9.2 months (PϽ.001 for both). The mean DFS and OS for women were 151.0±11.2 and 163.0±10.9 months, respectively. In contrast, men had 116.0±9.5 months' DFS and 127.0±9.0 months' OS (P=.01 for both). By multivariate analysis, lymph node status was the most predictive variable for DFS and OS (PϽ.001 for both). Sex tended to affect OS (P=.02) but did not achieve prognostic significance on DFS (P=.09). Other factors such as location, ulceration, histological type, and mitoses per square millimeter failed to show any prognostic significance. Stratification into 3 age groups (65-70, 71-80, and Ͼ80 years) had no significant effect on DFS (P=.95) or OS (P=.92).
Conclusions: Lymph node status is the most important prognostic factor in older patients with intermediatethickness melanoma. Identification of high-risk factors may help stratify these patients for recommendation of more aggressive treatment or adjuvant therapies. Among these patients, age alone was not a significant prognostic factor in the clinical management of melanoma.
Arch Surg. 2003; 138:1135 -1138 T HE INCIDENCE of cutaneous melanoma is rising steadily, and the rate of increase is among the highest for any form of cancer. 1,2 Although the incidence of melanoma in younger populations appears to be leveling off or decreasing, the rate continues to rise in older persons. 3, 4 As the geriatric population increases in the United States, melanoma will be an important public health issue in this century.
Many prognostic factors have been studied for cutaneous melanoma: thickness, ulceration, clinical stage, anatomical site, mitoses per square millimeter, sex, and age. Although the reliability of age as a prognostic factor is debatable, several studies [4] [5] [6] [7] suggest that age has an important prognostic use. Our objective was to determine the role of age as a prognostic factor in intermediate-thickness melanoma.
METHODS
We identified 213 patients aged 65 years or older with intermediate-thickness melanoma (1-4 mm) in the registry of the Department of Surgical Oncology from May 12, 1961 , to October 29, 1998. All patients had received surgical treatment from the department's faculty and it consisted of surgical wide excision of the primary lesion. Complete regional lymph node dissection (LND) was performed simultaneously in 128 of the 213 patients.
Data on the 213 patients were analyzed to evaluate known prognostic variables such as age, sex, histological characteristics, location of primary tumor, number of mitoses per square millimeter, and ulceration relative to disease-free survival (DFS) and overall survival (OS). We also analyzed the effect of nodal status on DFS and OS in the 128 patients who underwent LND. We evaluated the prognostic variables using the KaplanMeier method, with log-rank comparison. Multivariate analyses were done using Cox regression analysis. Differences were significant at PϽ.05. Analyses were performed using SPSS software, version 10.1 (SPSS Inc, Chicago, Ill). Death due to melanoma was considered the only event for OS. Disease-free survival events included regional recurrences and distant metastases. Data are expressed as mean ± SD unless otherwise indicated. 
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TUMOR CHARACTERISTICS
Primary tumor location was in the lower extremity in 67 (31.5%), trunk in 57 (26.8%), head and neck in 49 (23.0%), and upper extremity in 40 (18.8%) ( Table 1 ). The most common histological finding was superficial spreading melanoma in 100 patients (46.9%). Seventy-seven patients (36.2%) had nodular melanoma, 23 (10.8%) had acral lentiginous melanoma, and 11 (5.2%) had lentigo maligna melanoma. Melanoma was ulcerated in 65 patients (30.5%). We identified 88 patients (41.3%) with 5 or more mitoses per square millimeter.
Of the 128 patients who underwent elective LND, 36 (28.1%) had node-positive disease. Table 1 summarizes the patient and tumor characteristics.
SURVIVAL
Mean follow-up was 49 months. Mean DFS and OS for the entire population were 142 and 146 months, respectively (Figure 1) . Results of univariate analyses of several prognostic factors with respect to DFS and OS are given in Table 2 . Univariate analysis predicted worse DFS and OS when patients had positive results of pathological examination after LND (PϽ.001 for both) and when the patient was male (P=.01 for both). Mean DFS and OS for nodepositive patients were 36.0±9.6 and 56.0±10.6 months, respectively. Mean DFS and OS for node-negative patients were 155.0 ± 9.8 and 166.0 ± 9.2 months, respectively (PϽ.001 for both). Mean DFS and OS for women were 151.0±11.2 and 163.0±10.9 months, respectively. In contrast, men had 116.0±9.5 months and 127.0±9.0 months of DFS and OS, respectively (P=.01 for both). Other factors such as location, ulceration, histological type, and mitoses per square millimeter failed to show any prognostic significance. Stratification into 3 age groups (65-70, 71-80, and Ͼ80 years) demonstrated no significant effect on DFS (P=.95) or OS (P=.92) (Figure 2) .
By multivariate analysis ( Table 3 and Figure 3 ), lymph node status was the most predictive variable for DFS and OS (PϽ.001 for both). Sex significantly affected OS (P = .02) but did not achieve prognostic significance on DFS (P = .09). After multivariate analysis, other prognostic factors did not demonstrate significance relative to the outcomes.
COMMENT
Older patients comprise an important group among those with melanoma. The incidence in the geriatric popula- tion continues to rise, although the incidence in the younger populations appears to be leveling off or decreasing. 2, 3 Nearly 50% of all melanoma deaths in the United States are in white men older than 50 years. 8 Similarly, 50% of deaths from melanoma in New South Wales, Australia, occur in males older than 50, although this age group only accounts for 12% to 14% of the population. 9 The mean DFS and OS for all patients in our series were 142 and 146 months, respectively. Univariate analysis of the prognostic variables in our cohort of patients demonstrated significantly worse survival in patients with node-positive disease. Multivariate analysis showed lymph node status to be most predictive of survival. Our data suggest that older patients with intermediate-thickness melanoma may have favorable survival with aggressive surgery alone when disease has not spread to the regional lymph nodes.
In our study, women had an increase in OS that did not achieve prognostic significance on DFS. Whether this increase in OS is due to a hormonal factor or an increased life expectancy for women in the United States is hard to substantiate. In addition, we did not evaluate the effect of use of exogenous estrogen on DFS or OS. In comparison, O'Doherty et al 10 reported that older men had a poorer prognosis than older women, but this difference could relate to a lower cutoff age used in their study. The potential sex difference in prognostic outcome may likely be due to differences in physiological levels of sex hormones. However, there is no clear evidence that hormonal factors have a protective role in melanoma.
Stratification of the sample into 3 age groups (65-70, 71-80, and Ͼ80 years) revealed that the DFS and OS were similar among the groups (Figure 3) . Simply stated, an 80-year-old patient has the same survival as a 65-yearold patient with the same stage of melanoma. Consequently, our data suggest that age alone should not be used as the exclusion criterion for aggressive surgery in the properly selected patient.
One of the reasons cited for the increased mortality among older patients with melanoma is immunosenescence. As we age, the immune system declines in function, resulting in a decreased capacity to fight infection and malignancy. 11 Older persons may have reduced numbers and altered function of Langerhans cells, thus leading to a compromised immune system. 12 Another reason cited for the higher mortality in older persons is the increased thickness of melanoma at diagnosis. Levine et al 13 hypothesize that decreased skin thickness in older persons permits a deeper level of invasion for lesions of similar thickness. However, this hypothesis is not supported by findings of Loggie et al, 6 who were not able to correlate increased level of invasion with a given skin thickness. Whether immunose- nescence or skin thickness plays any important role in the OS of older patients with melanoma is uncertain. Sentinel lymph node (SLN) biopsy has become widely accepted as a method of staging the regional lymph nodes in patients with melanoma. Outpatient biopsy can be performed at the same time as wide local excision of the primary melanoma. It is less morbid than an elective LND and is cost-effective. The advantage of SLN biopsy in melanoma is that it spares 75% to 80% of patients the need for complete regional lymphadenectomy, while identifying those patients at highest risk. The presence of a positive SLN has been shown to be the single most important prognostic factor for recurrence and survival. We perform SLN biopsies on all patients with intermediate-thickness melanoma (1-4 mm). We also perform SLN biopsies on those with melanomas less than 1 mm if they demonstrate ulceration or Clark invasion level IV or V. The usefulness of SLN biopsies on lesions thicker than 4 mm is not clearly defined. In a recent study by Essner et al, 14 the SLN status in thick melanoma was predictive of DFS but not reflective of OS. We routinely perform completion LND if the SLN is found to be positive. The use of this minimally invasive procedure in older populations may help select those who may benefit from completion LND or adjuvant therapy.
Public health initiatives should inform older populations that melanoma is a significant and potentially curable health problem. Marks et al 15 demonstrated the mismatch between the age at which pigmented lesions are excised and older age at which melanoma is likely to occur. Among patients aged 21 to 40 years, the ratio of benign nevus to melanoma among excised lesions was 27.2, compared with 1.4 in those older than 60. 15 Consequently, health care practitioners who work with older persons should increase melanoma screening.
In conclusion, lymph node status is the most important prognostic factor in older patients with intermediatethickness melanoma. Identification of high-risk factors 16 may help stratify these patients for recommendation of more aggressive treatment or adjuvant therapies. Among these patients, age alone was not a significant prognostic factor in the clinical management of melanoma. Therefore, treatment of patients with melanoma who are 65 years or older should be based on prognostic factors, not advanced age. 
